Literature DB >> 29948832

Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited.

Giorgio Derchi1, Carlo Dessì2, Patrizio Bina2, Maria Domenica Cappellini3, Antonio Piga4, Silverio Perrotta5, Immacolata Tartaglione5, Marianna Giuditta3, Filomena Longo4, Raffaella Origa6, Antonella Quarta7, Valeria Pinto8, Gian Luca Forni9.   

Abstract

Heart disease remains a leading cause of morbidity and mortality in transfusion-dependent thalassemia (TDT), which can be attributed to several factors but primarily develops in the setting of iron overload. This was a retrospective cohort study utilizing Webthal® patient data from five major centers across Italy. Patients without heart disease were followed-up for 10 years (2000-2010) and data were collected for demographics, splenectomy status, serum ferritin and hemoglobin levels, and comorbidities associated with heart disease. Among 379 patients analyzed (mean age 22.9 ± 5.1 years, 47.8% men), 44 (cumulative incidence: 11.6%) developed heart disease during the period of observation. Splenectomy (p = 0.002) and serum ferritin level (p < 0.001) were the only risk factors with significant association with heart disease. A serum ferritin threshold of ≥ 3000 ng/mL was the best predictor for the development of heart disease (86.4% sensitivity and 92.8% specificity, AUC: 0.912, 95% CI 0.852-0.971, p < 0.001). On multivariate analysis, only a serum ferritin level ≥ 3000 ng/mL remained significantly and independently associated with increased risk of heart disease (HR: 44.85, 95% CI 18.85-106.74), with a 5- and 10-year heart disease-free survival of 58 and 39%. The association between iron overload and heart disease in patients with TDT is confirmed, yet a new serum ferritin level of 3000 ng/mL to flag increased risk is suggested.

Entities:  

Keywords:  Heart disease; Iron overload; Serum ferritin; Thalassemia

Mesh:

Substances:

Year:  2018        PMID: 29948832     DOI: 10.1007/s11739-018-1890-2

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  21 in total

1.  Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.

Authors:  Dudley J Pennell; John B Porter; Maria Domenica Cappellini; Lee Lee Chan; Amal El-Beshlawy; Yesim Aydinok; Hishamshah Ibrahim; Chi-Kong Li; Vip Viprakasit; Mohsen S Elalfy; Antonis Kattamis; Gillian Smith; Dany Habr; Gabor Domokos; Bernard Roubert; Ali Taher
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

2.  On T2* magnetic resonance and cardiac iron.

Authors:  John-Paul Carpenter; Taigang He; Paul Kirk; Michael Roughton; Lisa J Anderson; Sofia V de Noronha; Mary N Sheppard; John B Porter; J Malcolm Walker; John C Wood; Renzo Galanello; Gianluca Forni; Gualtiero Catani; Gildo Matta; Suthat Fucharoen; Adam Fleming; Michael J House; Greg Black; David N Firmin; Timothy G St Pierre; Dudley J Pennell
Journal:  Circulation       Date:  2011-03-28       Impact factor: 29.690

3.  Lack of correlation between heart, liver and pancreas MRI-R2*: Results from long-term follow-up in a cohort of adult β-thalassemia major patients.

Authors:  Valeria Maria Pinto; Lorenzo Bacigalupo; Barbara Gianesin; Manuela Balocco; Lucia De Franceschi; Roberto Malagò; John Wood; Gian Luca Forni
Journal:  Am J Hematol       Date:  2018-01-09       Impact factor: 10.047

4.  Myocardial deformation in iron overload cardiomyopathy: speckle tracking imaging in a beta-thalassemia major population.

Authors:  Luca Antonio Felice Di Odoardo; Marianna Giuditta; Elena Cassinerio; Alberto Roghi; Patrizia Pedrotti; Marco Vicenzi; Veronica Maria Sciumbata; Maria Domenica Cappellini; Alberto Pierini
Journal:  Intern Emerg Med       Date:  2017-04-29       Impact factor: 3.397

5.  Survival in medically treated patients with homozygous beta-thalassemia.

Authors:  N F Olivieri; D G Nathan; J H MacMillan; A S Wayne; P P Liu; A McGee; M Martin; G Koren; A R Cohen
Journal:  N Engl J Med       Date:  1994-09-01       Impact factor: 91.245

6.  Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major.

Authors:  P Kirk; M Roughton; J B Porter; J M Walker; M A Tanner; J Patel; D Wu; J Taylor; M A Westwood; L J Anderson; D J Pennell
Journal:  Circulation       Date:  2009-10-02       Impact factor: 29.690

7.  High nontransferrin bound iron levels and heart disease in thalassemia major.

Authors:  Antonio Piga; Filomena Longo; Lorena Duca; Simona Roggero; Tiziana Vinciguerra; Roberto Calabrese; Chaim Hershko; Maria Domenica Cappellini
Journal:  Am J Hematol       Date:  2009-01       Impact factor: 10.047

8.  A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA).

Authors:  Dudley J Pennell; John B Porter; Antonio Piga; Yongrong Lai; Amal El-Beshlawy; Khawla M Belhoul; Mohsen Elalfy; Akif Yesilipek; Yurdanur Kilinç; Tomasz Lawniczek; Dany Habr; Marianne Weisskopf; Yiyun Zhang; Yesim Aydinok
Journal:  Blood       Date:  2014-01-02       Impact factor: 22.113

9.  Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone.

Authors:  John B Porter; John Wood; Nancy Olivieri; Elliott P Vichinsky; Ali Taher; Ellis Neufeld; Patricia Giardina; Alexis Thompson; Blaine Moore; Patricia Evans; Hae-Young Kim; Eric A Macklin; Felicia Trachtenberg
Journal:  J Cardiovasc Magn Reson       Date:  2013-05-20       Impact factor: 5.364

10.  Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance.

Authors:  Bernadette Modell; Maren Khan; Matthew Darlison; Mark A Westwood; David Ingram; Dudley J Pennell
Journal:  J Cardiovasc Magn Reson       Date:  2008-09-25       Impact factor: 5.364

View more
  3 in total

1.  Prevalence and prognostic impact of left ventricular non-compaction in patients with thalassemia.

Authors:  Rodolfo Bonamini; Massimo Imazio; Riccardo Faletti; Marco Gatti; Borejda Xhyheri; Marco Limone; Filomena Longo; Antonio Piga
Journal:  Intern Emerg Med       Date:  2019-06-25       Impact factor: 3.397

Review 2.  Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series.

Authors:  Valeria Maria Pinto; Gian Luca Forni
Journal:  Int J Mol Sci       Date:  2020-11-20       Impact factor: 5.923

3.  The relationships between pancreatic T2* values and pancreatic iron loading with cardiac dysfunctions,  hepatic and cardiac iron siderosis among Egyptian children and young adults with β-thalassaemia major and sickle cell disease: a cross-sectional study.

Authors:  Khaled Salama; Amina Abdelsalam; Hadeel Seif Eldin; Eman Youness; Yasmeen Selim; Christine Salama; Gehad Hassanein; Mohamed Samir; Hanan Zekri
Journal:  F1000Res       Date:  2020-09-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.